Sanofi US News

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

- Late-breaking oral abstract presented at the World Congress of Gastroenterology -

- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -

- Praluent continues to be available to patients in the U.S. -

- First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis -